🔗 Share this article

While America proceeds with historic adjustments to its vaccination schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about Covid shots in the pandemic and has concentrated on alleged deaths following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Program

Agency leaders had intended to announce radical changes to the pediatric vaccine schedule in December, bringing the US with the Danish immunization schedule, it is understood – a major change that would place the US at odds with a large portion of the world with insufficient data for public health gain. The planned update has been pushed back until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

A Shift at the FDA

This interim role could signify a strengthened alliance between the drug and vaccine branches as Høeg and Prasad solidify control at the agency – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for halting some childhood immunization guidelines in the US in order to be more like Denmark, a nation with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

Høeg has no apparent track record in pharmaceutical research, approval processes or management, which has been standard for former leaders of the CBER. She has worked at the FDA as a key advisor to the agency head and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in leading a large organization. She lacks background in drug approvals.”

Past commissioners of the center would “grasp legal statutes and the science of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who ran the center have had.”

The drug center has an vast range of responsibilities at the FDA, she stated.

“Many people just focuses on the new drug program, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one have to be supervised,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a major administrative component to the position, which manages more than 5,000 employees. “It is a massive administrative position, if you perform it correctly,” she added.

Agency Reaction and Disputed Policies

When asked about concerns about Dr. Høeg's credentials and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a press secretary stated that the “inquiries rely on inaccurate premises”.

“This background aligns with the responsibilities of her role,” the representative explained, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed rapid therapy clearance system that reportedly troubled her preceding directors. “By what process are these drugs being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There is a lot of secrecy happening at the FDA right now.”

Overall, he stated, “the agency appears to be shifting towards laxer regulations of most medications, aside from vaccines.”

Established History on Vaccines

With vaccines, Høeg has a more established, if troubling, past, Howard have noted. She published a research paper using unverified public submissions to estimate the frequency of myocarditis following Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the incoming administration encompassed revising rules for new vaccines and discontinuing “unnecessary” immunizations, she stated following the vote on a podcast. At the FDA, Høeg has according to sources floated the idea of excluding young men from getting COVID-19 vaccinations.

“She’s an complete ideologue who begins with her beliefs and reverse-engineers to accommodate the science in a highly deceptive, fraudulent way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|